Clopidogrel-statin interaction: A mountain or a mole hill?

American Heart Journal

Volumn 152, Issue 2, 2006, Pages 200-203

  Steinhubl, Steven R ^a   Akers, W Scott ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450; ERYTHROMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; RIFAMPICIN; TROLEANDOMYCIN;

ACUTE CORONARY SYNDROME; AUTOMATION; CLINICAL TRIAL; COHORT ANALYSIS; DATA BASE; DRUG EFFECT; EDITORIAL; FLOW CYTOMETRY; HUMAN; MEDICAL LITERATURE; PERCUTANEOUS CORONARY INTERVENTION; POPULATION RESEARCH; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

BLOOD PLATELETS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; PRAVASTATIN; PYRROLES; TICLOPIDINE;

EID: 33746238813     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.01.001     Document Type: Editorial

References (21)

1. Lau W.C., Waskell L.A., Watkins P.B., et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107 (2003) 32-37
2. Zhou S., Yung Chan S., Cher Goh B., et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44 (2005) 279-304
3. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
4. Neubauer H., Gunesdogan B., Hanefeld C., et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function-a flow cytometry study. Eur Heart J 24 (2003) 1744-1749
5. Mach F., Senouf D., Fontana P., et al. Not all statins interfere with clopidogrel during antiplatelet therapy. Eur J Clin Invest 35 (2005) 476-481
6. Hochholzer W., Trenk D., Frundl D., et al. No impact of statins metabolized by CYP3A4 on the antiplatelet effect and the clinical outcome after a 600 mg loading dose of clopidogrel in patients undergoing elective coronary angiography. Eur Heart J 26 Abstract Suppl (2005) 483
7. Mitsios J.V., Papathanasiou A.I., Rodis F.I., et al. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 109 (2004) 1335-1338
8. Serebruany V.L., Midei M.G., Malinin A.I., et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 164 (2004) 2051-2057
9. Muller I., Besta F., Schulz C., et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 108 (2003) 2195-2197
10. Gorchakova O., von Beckerath N., Gawaz M., et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary stenting. Eur Heart J 25 (2004) 1898-1902
11. Smith S.M., Judge H.M., Peters G., et al. Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. Platelets 15 (2004) 465-474
12. Zsamboki E.T., Beres B.J., Vargova K., et al. Statin therapy has an antiplatelet effect and does not interfere with the loading dose of clopidogrel in patients with ischemic heart disease. Eur Heart J 26 Abstract Suppl (2005) 485
13. Piorkowski M., Weikert U., Schwimmbeck P.-L., et al. ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin. Thromb Haemost 92 (2004) 614-620
14. Vinholt P., Poulsen T.S., Hallas J., et al. The antiplatelet effect of clopidogrel is not attenuated by treatment with CYP3A4 metabolised statins in patients with stable ischemic heart disease. Eur Heart J 26 (2005) 438-443
15. Mukherjee D., Kline-Rogers E., Fang J., et al. Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. Heart 91 (2005) 23-26
16. Saw J., Steinhubl S.R., Berger P.B., et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 108 (2003) 921-924
17. Wienbergen H., Gitt A.K., Schiele R., et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 92 (2003) 285-288
18. Lim M.J., Spencer F.A., Gore J.M., et al. Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. Eur Heart J 26 (2005) 1063-1069
19. Brophy J.M., Babapulle M.N., Costa V., et al. Drug interactions following percutaneous coronary intervention-a pharmacoepidemiologic study. Am Heart J (2005) [in press]
20. Ray K.K., Cannon C.P., McCabe C.H., et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 46 (2005) 1405-1410
21. Yusuf S., Mehta S.R., Zhao F., et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 107 (2003) 966-972